Scholars Central

Conference abstractPublished 26 Jun 2014

Novel therapies for treating hyponatremia

Authors: Michael F Michelis

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

T he treatment of hyponatremia, especially euvolemic and hypervolemic hyponatremia, has changed with the development of vasopressin receptor antagonists. Conivaptan, a vasopressin receptor antagonist, has recently been approved by the FDA in the USA . This report summarizes one center?s experience with ten patients treated with this new intravenous drug. The patients had serum sodium levels <128 mEq/l. Conivaptan was given as a 20-mg intravenous loading dose followed by a 20-mg continuous 24-h infusion. Six of the ten patients had an excellent response to the therapy with serum sodium increasing by a mean of 8.5±0.8 mEq/l (increases ranged from 7 to 12 mEq/l over 24 h. Tolvaptan, an oral, selective arginine vasopressin (AVP) V2 receptor antagonist has also been approved in the USA. This report also summarizes experience with thirteen patients treated for hyponatremia with one 15-mg dose of tolvaptan. Eight patients had a diagnosis of the syndrome of inappropriate antidiuretic hormone (SIADH), and five patients had a diagnosis of congestive heart failure (CHF). The mean increase in SNa of 6.4 mEq/L (range 2-10 mEq/L) 24 h post-tolvaptan was not different in the two groups of patients, but SIADH patients had higher pre and post-tolvaptan SNa levels. Urine osmolalities (UOsm) decreased in all patients, but the patients with SIADH had significantly higher baseline UOsm and a larger decrease in UOsm 12 h post-tolvaptan administration. The magnitude of increase in SNa levels was inversely related to pretolvaptan AVP levels in the SIADH subgroup (r=-0.7, P=0.01. The data show that tolvaptan may produce differing responses in disparate patient groups

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nephrology & Therapeutics.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nephrology & Therapeutics
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Michael F Michelis”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels